2+ hour, 17+ min ago   (1581+ words) Global trends reveal a growing burden of hypertension-related CKD despite advances in blood pressure management. The global burden of chronic kidney disease attributable to hypertension (HT-CKD) has increased substantially over the past 3 decades, driven largely by aging populations and modifiable…...

19+ hour, 52+ min ago   (1163+ words) Your daily dose of the clinical news you may have missed. Jorge E. Cortes, MD; Hagop Kantarjian, MD; Neil P. Shah, MD, PhD; Kendra Sweet, MD Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD Sammy Saab, MD, MPH, AGAF,…...

1+ week, 9+ hour ago   (1317+ words) Your daily dose of the clinical news you may have missed. Jeremie Calais, MD, PhD; Qian Qin, MD Misty D. Shields, MD, PhD; Horace Tang, MD Erminia Massarelli, MD, PhD, MS; Parth Khade, MD Misty D. Shields, MD, PhD; Chandler Park, MD,…...

1+ week, 1+ day ago   (116+ words) A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes. A national survey of 600 primary care physicians (PCPs) examined perceptions and use of urine albumin-to-creatinine ratio (UACR) testing in…...

1+ week, 2+ day ago   (216+ words) FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes. The US Food and Drug Administration has accepted for Priority Review a supplemental biologic license application for Tzield (teplizumab-mzwv) to…...

1+ week, 5+ day ago   (321+ words) The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026. The US Food and Drug Administration has accepted for filing a supplemental new drug…...

2+ week, 5+ hour ago   (1731+ words) Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents. A signficant milestone was the FDA approval of the subcutaneous autoinjector for lecanemab (Leqembi; Eisai)…...

2+ week, 2+ day ago   (491+ words) Agitation is among the most common'and most disruptive'neuropsychiatric symptom of Alzheimer disease, yet new data suggest it remains widely misunderstood by the very people most affected by it: family caregivers. The following transcript has been lightly edited for style and…...

2+ week, 5+ day ago   (1807+ words) Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies. Brad Dickerson, MD, professor of neurology at Harvard Medical School and director of…...

9+ mon, 1+ week ago   (283+ words) Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile. Trontinemab is an investigational Brainshuttle" bispecific 2+1 amyloid-beta (A) antibody engineered to enhance delivery across the blood-brain barrier and permit rapid reduction of…...